130 related articles for article (PubMed ID: 35661561)
1. Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients.
Toniutto P; Cussigh A; Cmet S; Bitetto D; Fornasiere E; Fumolo E; Fabris M; D'Aurizio F; Fabris C; Grillone L; Sartor A; Curcio F; Falleti E
Liver Int; 2023 Feb; 43(2):452-461. PubMed ID: 35661561
[TBL] [Abstract][Full Text] [Related]
2. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients.
Toniutto P; Cussigh A; Cmet S; Fabris M; Curcio F; Bitetto D; Fornasiere E; Fumolo E; Falleti E
Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514981
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
[TBL] [Abstract][Full Text] [Related]
6. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
[TBL] [Abstract][Full Text] [Related]
7. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients.
Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers.
Khalaileh A; Imam A; Jammal A; Hakimian D; Amer J; Shafrir A; Milgrom Y; Massarwa M; Hazou W; Khader M; Safadi R
Hepatol Commun; 2023 Feb; 7(2):e0025. PubMed ID: 36724131
[TBL] [Abstract][Full Text] [Related]
9. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of SARS-CoV-2 Vaccine in Kidney Transplant Recipients: A Cross-Sectional Study in Korea.
Song SH; Chung KY; Jee Y; Chung HS; Kim K; Minn D; Kim SK
J Korean Med Sci; 2023 Feb; 38(5):e22. PubMed ID: 36747360
[TBL] [Abstract][Full Text] [Related]
12. Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients.
Miura M; Fukumoto M; Komatsu N; Shuto R; Harada H; Sasaki H
Int J Urol; 2022 Dec; 29(12):1505-1510. PubMed ID: 36070502
[TBL] [Abstract][Full Text] [Related]
13. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents.
Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
Pediatr Int; 2022 Jan; 64(1):e15331. PubMed ID: 36331234
[TBL] [Abstract][Full Text] [Related]
17. Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Mori K; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2023 Sep; 13(1):15098. PubMed ID: 37699969
[TBL] [Abstract][Full Text] [Related]
18. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
Hoffman TW; Meek B; Rijkers GT; van Kessel DA
Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
[TBL] [Abstract][Full Text] [Related]
20. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
